Fraiser Kansteiner

As myriad pharma industry attempts to challenge the Inflation Reduction Act (IRA) fall flat, Johnson & Johnson is settling into a reality of pricing rebates and Medicare drug cost negotiations.

Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade.

Back in February, Novo Holdings laid out a $16.5 billion deal to snap up contract manufacturing giant Catalent.

As with GSK before it, Daewoong Bio's manufacturing misstep has resulted in a ban for the Korean company from China's bulk-buy drug procurement program.

As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.

After making major manufacturing outlays in places like China and the United States earlier this year, Novo Nordisk is returning to its Danish roots.

From flubbing data to performing aseptic processing with torn and stained gowns, Brassica Pharma’s recent warning letter from the FDA reads like a textbook example of what not to do when the U.S.

While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the

Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen's anti-amyloid Alzheimer's disease med Leqembi has come up short in the eyes of European regulators.

After Eli Lilly's Olumiant won the distinction of becoming the first med approved by the FDA to treat the follicle-attacking autoimmune disease alopecia areata, Pfizer followed up with a green light for its own JAK inhibitor, Litfulo, the following year.